⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004057 | 0.92 | — | — | |
| Ethylenediamine SCHEMBL4788800 | 0.91 | ODC1 (0.32) | — | |
| SCHEMBL12675500 | 0.89 | DNM1 (0.42) | — | |
| SCHEMBL14261858 | 0.89 | — | — | |
| SCHEMBL6025052 | 0.89 | DNM1 (0.42) | — | |
| SCHEMBL8860051 | 0.81 | — | — | |
| SCHEMBL10814572 | 0.78 | — | — | |
| SCHEMBL10819042 | 0.78 | — | — | |
| SCHEMBL4322351 | 0.77 | — | — | |
| Propane SCHEMBL11757435 | 0.74 | CYP3A4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202727-A1 | USE OF AGONISTS OF GABAB RECEPTORS AND PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, IN THE THERAPY OF MAINTAINING NICOTINE ABSTINENCE IN NICOTINE-DEPENDENT PATIENTS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001008675-A1 | USE OF AGONISTS OF GABAB RECEPTORS AND PHARMACEUTICALLY ACCEPTABLE DERIVATES THEREOF, IN THE THERAPY OF MAINTAINING NICOTINE ABSTINENCE-DEPENDENT PATIENTS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) | 2001-02-08 | — | — | WO | claimed |
| EP-0533352-A2 | Gaba receptor agonists to treat bladder instability | LYNXVALE LIMITED (GB) | 1993-03-24 | — | — | EP | claimed |
| WO-2019187740-A1 | AQUEOUS COATING COMPOSITION CONTAINING CALCIUM HYDROXIDE AND/OR MAGNESIUM HYDROXIDE | 関西ペイント株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-9399145-B2 | Nanoscale neuromodulating platform for retina neuron activation apparatus and method | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20160129277-A9 | Nanoscale Neuromodulating Platform for Retina Neuron Activation Apparatus and Method | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2016-05-12 | — | — | US | disclosed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130237899-A1 | Nanoscale Neuromodulating Platform for Retina Neuron Activation Apparatus and Method | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-5516767-A | PRODRUG AS HYPOGLYCEMIC AGENT | SANDOZ LTD. (CH) | 1996-05-14 | — | — | US | disclosed |
| US-5412137-A | Hypoglycemic agents | SANDOZ LTD. (CH) | 1995-05-02 | — | — | US | disclosed |
| CN-1086217-A | The derivative of Phosphinyloxy propanaminium inner salt | SANDOZ LTD (CH) | 1994-05-04 | — | — | CN | disclosed |
| CN-1086217-A | The derivative of Phosphinyloxy propanaminium inner salt | SANDOZ LTD (CH) | 1994-05-04 | — | — | CN | disclosed |
| EP-0574355-A1 | Phosphinyloxy propanaminium inner salt derivatives | SANDOZ LTD. (CH) | 1993-12-15 | — | — | EP | disclosed |
| EP-0533352-A2 | Gaba receptor agonists to treat bladder instability | LYNXVALE LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0356128-B1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-07-01 | — | — | EP | disclosed |
| WO-1990001936-A1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT AND INTERMEDIATES IN ITS SYNTHESIS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| EP-0356128-A2 | 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |